Severin Schwan, Roche CEO (AP Images)
Roche to read out even more data on megablockbuster Ocrevus in MS
It’s been three years since Roche hit the market with its megablockbuster MS drug Ocrevus — but the Swiss pharma isn’t done building on the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
